Clinical Trials Logo

Carcinogenesis clinical trials

View clinical trials related to Carcinogenesis.

Filter by:

NCT ID: NCT04525833 Recruiting - Clinical trials for Hepatocellular Carcinoma

Liver Disease and Other Systemic Diseases

Start date: January 1, 2020
Phase:
Study type: Observational

Examine the association of chronic liver diseases (including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis, and hepatocellular carcinoma) with other systemic diseases by retrospectively analyzing the data from the Hospital Database of Buddhist Tzu Chi Medical Foundation.

NCT ID: NCT04278989 Recruiting - Clinical trials for Squamous Cell Cancer of the Oral Cavity

Inhibition of Oral Tumorigenesis by Antitumor B

Start date: April 22, 2022
Phase: Early Phase 1
Study type: Interventional

This is a window of opportunity study of Anti-tumor B (ATB). Anti-tumor B is a botanical agent composed of six Chinese herbs: Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera.

NCT ID: NCT04250727 Completed - Clinical trials for Tobacco Use Disorder

Switching to Potential Reduced Exposure Products in Adult Smokers

ZYN
Start date: May 1, 2021
Phase: N/A
Study type: Interventional

This study aims to assess the feasibility, acceptability, and the potential harm reduction of switching to potentially lower risk, oral nicotine pouches in adult smokers. Part One of this study aims to assess the interest of current smokers in switching to an e-cigarette device (i.e. JUUL) compared to alternative non-combustible tobacco products (i.e. smokeless tobacco/snus) and/or medicinal nicotine via survey. Part Two will consist of a pilot study of 30 non-treatment seeking adult smokers to investigate within-person changes in smoking behavior as a result of switching to different concentrations of oral nicotine pouch products (i.e. ZYN, 3mg and 6mg nicotine concentration). Additionally, by measuring bio-markers of tobacco exposure from baseline, this will allow the study to assess the potential for harm reduction in switching from cigarettes to oral nicotine pouches.

NCT ID: NCT04198896 Completed - Clinical trials for Atherosclerosis of Artery

The Sakakibara Health Integrative Profile of Atherosclerotic-Carcinogenesis Hypothesis (SHIP-AC)

SHIP-AC
Start date: January 2009
Phase:
Study type: Observational [Patient Registry]

As previously reported (IJC Heart & Vasculature 2017; 17: 11.), our epidemiological analysis showing high incidence of cancers in patients with atherosclerotic cardiovascular diseases as compared with those with non-atherosclerotic cardiovascular diseases may imply a clinical possibility of a role of atherosclerosis in cancer developments. In the present study, to address our hypothesis that cancer developments may come with a strength of atherosclerosis, we traced an incidence of cancers in a total of 8,856 patients with coronary artery diseases (CAD) for a median follow-up of 1,095 days (interquartile range, 719-1,469 days) using the Sakakibara Health Integrative Profile (SHIP) database.

NCT ID: NCT03955510 Active, not recruiting - Colorectal Cancer Clinical Trials

Abnormal Food Timing and Circadian Dyssynchrony in Alcohol Induced Colon Carcinogenesis

AFT
Start date: July 31, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to study the impact of Western lifestyle, including moderate alcohol consumption and delayed eating patterns on studying individuals' susceptibility to colorectal cancer. This study aims to increase our ability to identify individuals at risk for colorectal cancer in the future. Each subject will experience four conditions (each for one week in duration with a week +/- 2 days wash-out in between): (1) "right-time eating" / no alcohol, (2) "right-time eating" / with alcohol, (3) "delayed-eating" / no alcohol, (4) "delayed-eating" / with alcohol. The order of experiments will be randomized [concealed randomization]. All subjects will undergo unprepped sigmoidoscopy after each week of intervention. In Aim 2, all subjects will have an option to undergo a 24h circadian assessment in the Biological Rhythms Research Lab after each week of intervention. The Investigator will assess (i) central circadian rhythms by collecting hourly salivary samples for melatonin assays and (ii) peripheral rhythm in the intestinal tract by buccal swabs once every 2h (12 time points) as well as by rectal sampling twice (every 12 hr). For Aim 3, sigmoidoscopy without sedation will be used to obtain colonic samples as the safe method compared to colonoscopy, which has some small but finite risks associated with the procedure (e.g, bleeding or perforation) as well as sedation.

NCT ID: NCT03776435 Recruiting - Appendicitis Clinical Trials

CT Carcinogenic Risk in Patients With Appendicitis

Start date: January 15, 2018
Phase:
Study type: Observational

The purpose of this study is to compare the incidence rate of leukemia between CT-exposed and CT-unexposed group in patients who underwent appendectomy in South Korea.

NCT ID: NCT03742869 Recruiting - Clinical trials for Human Papillomavirus

HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma

Start date: November 10, 2018
Phase:
Study type: Observational

This study aims to analyze the multi-omics results between uterine cervical adenocarcinoma patients with and without human papillomavirus (HPV) infections. The multi-omics profiles include genome wide association study (GWAS), whole exome sequencing, analysis of transcriptomics and metabolomics. The HPV integration status is interpreted by GWAS. A comprehensive multi-omics will reveal the role of HPV integration in the molecular mechanism of tumorigenesis and prognosis of uterine cervical adenocarcinoma.

NCT ID: NCT03742856 Recruiting - Clinical trials for Epithelial Ovarian Cancer

A Multi-omics Study of Epithelial Ovarian Cancer

Start date: November 10, 2018
Phase:
Study type: Observational

This study aims to analyze the multi-omics results between epithelial ovarian cancer (EOC) patient with different FIGO stages and pathological subtypes. The multi-omics profiles include whole exome sequencing, analysis of transcriptomics and metabolomics. A comprehensive multi-omics will reveal the invasiveness and tumorigenesis of EOC.

NCT ID: NCT03261752 Not yet recruiting - Colo-rectal Cancer Clinical Trials

New Genes in the Carcinogenesis of Colorectal Cancer

Start date: October 1, 2018
Phase:
Study type: Observational

Colo rectal cancer is one of the greatest ,mutual malignancies worldwide ,accounting for an estimated 1.3 million new cases and >500,000 mortality ⁄ year . is the fourth leading cause of cancer-associated mortality worldwide with speedily ,cumulative ,occurrence rate in the worldwide

NCT ID: NCT03188315 Not yet recruiting - Clinical trials for DNA Virus Infections

Studies of Small DNA Virus Encoded Oncogenes in Viral Carcinogenesis Using Laboratory Model Systems

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

Cancer is a devastating disease, presenting an immense disease burden to affected individuals and their families as well as health care systems with 10.9 million new cases and 6.7 million deaths per year. Approximately 12% of human cancers worldwide are caused by oncoviruses infection with more than 80% of cases occurring in the developing world. Tumor viruses can be classified into two groups based on their genetic material; 1. DNA tumor viruses: 1. Small DNA tumor viruses (Papilloma viruses, Polyoma viruses and adenoviruses). 2. Complex DNA tumor viruses (Herpes viruses and Hepatitis B viruses). 2. RNA tumor viruses ( Hepatitis C viruses and human T-cell leukemia virus "HTLV"). There are around 100 types of HPV, with different variations in their genetic and oncogenic potential [5]. Thus, HPV genotypes are divided into 2 groups based on their vulnerability; High risk HPV (HR-HPV) and low risk HPV (LR-HPV). The HPV genome encodes several oncoproteins [5]. E6 and E7 are the main genes responsible for cell transformation mediated by HR-HPV, and they modulate the activities of cellular proteins that regulate the cell cycle. Thus, the presence of E6/E7 can be a specific marker for diagnosing precancerous lesions by HPV. Knowledge of the etiology of virus-mediated carcinogenesis, the networking of pathways involved in the transition from infection to cancer and the risk factors associated with each type of cancer, all suggest prophylactic and therapeutic strategies that may reduce the risk of virus-mediated cancer.